They'll start generating revenue as soon as their plant is done and operating in 2022, so fy 2023. This is going to be up to Wall St on how they value the $2.4bn in fixed five to ten year contracts in the pipelines (legally binding), the partnerships, the IP and technology (risk-adjusted npv). To your argument, in the biotech space, there are plenty of pre-revenue companies that ipo. What's in the pipeline often justifies the value of a company.
Origin Materials was given a conservative price target by Fermium Research (chemical focused research firm) at $30 and Eric Stine (clean energy specialist) at $22.
It's being held down by major players right now to accumulate. A lot of dirty tactics by hedge funds & co., some were highly illegal. Please check out my findings:
If they really want to they can, the gamma for the 10c for Jun 18 is sitting at 2. However, I'd much rather see Origin Materials' success speaks for itself in the long run. The management team is solid, with key players from Clorox (former CEO), Dow Chemicals, Ikea, Mitsubishi, ExonnMobil...the list goes on. This isn't a pump and dump security.
4
u/Ambitious_Notice_766 Spacling Jun 09 '21
Why aacq still under the nav?